Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 17/20 | 0.58 |
| ▸ | HTR2A | P28223 | 16/20 | 0.58 |
| ▸ | HTR2B | P41595 | 8/20 | 0.58 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.43 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845010 | 1.00 | HTR2C (0.58) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL5843697 | 0.82 | HTR2C (0.55) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL5843691 | 0.82 | HTR2C (0.55) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL2270191 | 0.81 | HASPIN (0.51) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL5843663 | 0.80 | HTR2C (0.53) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL5844510 | 0.79 | HTR2C (0.51) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL5844513 | 0.79 | HTR2C (0.51) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL5845389 | 0.77 | HTR2A (0.49) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL5845398 | 0.77 | HTR2A (0.49) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL31079920 | 0.72 | HTR2C (1.00) | HTR2CHTR2AHTR2BHTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129257-B1 | Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma | ALCON, INC. (CH) | 2006-10-31 | — | — | US | disclosed |
| US-20060069096-A1 | Pyrazolo[3,4-e]benzoxazoles for the treatment of glaucoma | DANTANARAYANA ANURA P | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069096-A1 | Pyrazolo[3,4-e]benzoxazoles for the treatment of glaucoma | PTGIR, PDE3A, TBXA2R | HTR2C 2389/4885HTR2A 3491/4885HTR2B 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.